Reuters Health News Summary

• Doctors are increasingly integrating artificial intelligence into cancer care to help navigate complex treatment decisions and support patients. • AI tools act as digital consults by aggregating evidence from rapidly evolving clinical trials, drug approvals, and resistance biology.

• Helus Pharma announced the results of its annual and special shareholder meeting held on September 22, 2026. • Shareholders approved a legal name change for the company from Cybin Inc. to Helus Pharma Inc. and appointed a new auditor.

• A new academic publishing platform launched this week to combine peer-reviewed scientific research with direct community expertise in public health studies. • The initiative pairs traditional clinical investigators with local populations to ensure health interventions reflect lived experiences and real-world needs.

• The National Institutes of Health (NIH) is currently operating the RECOVER initiative to understand, prevent, and treat long COVID. • The program uses observational studies tracking thousands of people and clinical trials to test interventions for cognitive issues, severe fatigue, and sleep abnormalities.

• The CEO of Helus Pharma will participate in a virtual mental-health summit on September 23. • The event will be a fireside chat webcast live at 9 a.m. EDT and later posted to the company's investor relations website.

• Stuff analyzed government policy documents and coalition agreements to track which health system promises were kept, partially kept, or broken. • The government achieved its goal to require the Ministry of Health to publish a new Medicines Strategy every three years.

• Helus Pharma presented new Phase 1/2a study data for its major depressive disorder candidate, HLP003, at Psych Congress 2026. • The company shared results regarding HLP003 and its broader program of NSAs, which are non-selective antidepressants.

• Helus Pharma presented new analyses of its HLP003 drug candidate for Major Depressive Disorder at Psych Congress 2026. • The company used poster presentations to detail the clinical profile of HLP003 and its Phase 3 PARADIGM program for adjunctive treatment.

• Zealand Pharma received a positive recommendation from the European Union's Committee for Medicinal Products for Human Use on Friday for its drug candidate Zeydovio. • The drug is designed to treat short bowel syndrome, a condition where the intestines are too short to absorb enough nutrients.

• Replimune received approval for Tudriqev, a medication delivered directly to tumors to treat cancer. • This localized delivery approach is also used by Amgen’s Imlygic to target therapeutics specifically at tumor sites.

• Cue Biopharma announced positive results from a Phase 2 clinical trial of its CUE-221 treatment for chronic spontaneous urticaria, a condition causing chronic hives. • The trial results demonstrated that the drug achieved significant efficacy and maintained a favorable safety profile for patients.